Table 4

Immune responses to vaccine antigens

AntigenNo. (%) of subjects respondinga
ACE527 recipient response to vaccine by day 41, 20 days after second vaccination (n = 36)Placebo recipient response to H10407 by day 70, 21 days after challenge (n = 27)
Serum IgGSerum IgAALSAnySerum IgGSerum IgAALSAny
LT-B24 (67)20 (56)33 (92)34 (94)14 (52)3 (11)17 (63)21 (78)
CFA/I13 (36)17 (47)20 (56)29 (81)8 (30)10 (37)18 (67)23 (85)
CS30 (0)4 (11)20 (56)22 (61)
CS66 (17)5 (14)6 (17)13 (36)
  • a Positive responses are defined as a 2.5-fold increase over baseline titer for serum IgG and IgA and as a 4-fold increase over baseline titer for ALS.